A PHASE 1/2 MULTICENTER, OPEN-LABEL OF FT-2102 AS A SINLGLE AGENT AND IN COMBINATION WITH AZACITIDINE OR CYTARABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROME WITH AN IDH1 MUTATION
2017-001051-32LEUCEMIA MIELOIDE AGUDAFundación Jiménez DíazInvestigador: ALONSO DOMINGUEZ JUAN MANUEL